Jul 24, 2024 6:00am EDT Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
Jul 11, 2024 7:15am EDT Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
Jul 11, 2024 7:00am EDT Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
Jun 10, 2024 7:00am EDT Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
May 10, 2024 7:00am EDT Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
Apr 30, 2024 7:00am EDT Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting